Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
  • A61M5/142—Pressure infusion, e.g. using pumps
  • A61M5/14212—Pumping with an aspiration and an expulsion action
  • A61M5/14232—Roller pumps
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
  • A61M5/142—Pressure infusion, e.g. using pumps
  • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
  • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type

Definitions

• the present disclosure relates generally to devices, systems, and methods for the delivery of pharmaceutical compositions to a patient. More particularly, the present disclosure relates to an anti-self-sealing element for a reservoir bag for an injector, tooling for forming such a reservoir bag, and associated methods.
• Wearable medical devices such as automatic injectors, have the benefit of providing therapy to the patient at a location remote from a clinical facility and/or while being worn discretely under the patient’s clothing.
• a wearable medical device can be applied to the patient’s skin and configured to automatically deliver a dose of the pharmaceutical composition within a predetermined time period after applying the wearable medical device to the patient’s skin, such as after a 27-hour delay. After the device delivers the pharmaceutical composition to the patient, the patient may subsequently remove and dispose of the device.
• Conventional automatic injectors typically include an internal reservoir bag in which the medicament is contained. Under certain circumstances, particularly when the reservoir bag is nearly empty, opposing sides of the reservoir bag can be drawn together under the suction of the pump of the injector. This can partially or wholly seal the outlet of the reservoir bag and prevents intended delivery of the medicament.
• Embodiments of the present disclosure are directed to a drug delivery device configured to deliver a medicament to a patient.
• the drug delivery device includes a cannula for piercing the patient’s skin, a pump for driving medicament to the cannula, and a reservoir bag fluidly connected to the pump.
• the reservoir bag includes a first membrane layer and a second membrane layer defining a medicament chamber. At least one of the first membrane layer and the second membrane layer includes a tunnel extending at least partially into the medicament chamber.
• the reservoir bag is an internal reservoir bag contained within an internal region of the drug delivery device.
• the first membrane layer is asymmetric relative to the second membrane layer.
• the first membrane layer is symmetric relative to the second membrane layer.
• a surface area of the second membrane layer is greater than a surface area of the first membrane layer.
• a surface area of the second membrane layer is approximately the same as a surface area of the first membrane layer.
• the tunnel has a raised profile.
• the tunnel defines a flow channel in fluid communication with a port of the reservoir bag.
• the tunnel extends an entire length of the medicament chamber.
• the tunnel terminates at an intermediate location within the medicament chamber.
• the tunnel is sufficiently strong to maintain shape under vacuum produced by the pump.
• the tunnel prevents the first and second membrane layers from laying entirely flat against one another.
• FIG. 1 Other embodiments of the present disclosure are directed to a vacuum molding device for forming a reservoir bag of a drug delivery device.
• the vacuum molding device includes a die defining a cavity, and a vacuum channel extending from the cavity.
• the cavity corresponds to a profile of a tunnel to be formed in the internal reservoir bag.
• the vacuum channel is configured to draw at least one of a first membrane layer and a second membrane layer of the reservoir bag into the cavity.
• the vacuum molding device further includes a sealing plate configured to join the first membrane layer to the second membrane layer.
• the sealing plate includes one or more prongs configured to join the first membrane layer to the second membrane layer.
• the sealing plate is configured to be moved toward the die.
• the die includes one or more passageways through which one or more profiles of the sealing plate extend.
• FIG. 1 Other embodiments of the present disclosure are directed to a pinch-forming device for forming a reservoir bag of a drug delivery device.
• the pinch-forming device includes a pair of pinching grips configured for engaging a second membrane layer of the reservoir bag on opposite sides of a tunnel to be formed in the second membrane layer, and an actuator configured for drawing the pinching grips toward one another to form the tunnel in the second membrane layer.
• a first membrane layer of the reservoir bag remains stationary as the actuator draws the pinching grips toward one another.
• the actuator includes a cylinder.
• the pinch-forming device further includes a sealing plate configured to join the first membrane layer to the second membrane layer.
• the sealing plate includes one or more prongs configured to join the first membrane layer to the second membrane layer.
• FIG. 1 Other embodiments of the present disclosure are directed to a method of forming a reservoir bag of a drug delivery device.
• the method includes positioning a first membrane layer and a second membrane layer on a die, the die defining a cavity corresponding to a profile of a tunnel to be formed in the internal reservoir bag, applying a vacuum to the cavity to draw the second membrane layer into the cavity, and joining the first membrane layer to the second membrane layer to lock the tunnel in place.
• joining the first membrane layer to the second membrane layer includes engaging at least one of the first membrane layer and the second membrane layer with a heated sealing plate.
• the die includes one or more passageways through which the one or more profiles of the heated sealing plate extend.
• Other embodiments of the present disclosure are directed to a method of forming a reservoir bag of a drug delivery device.
• the method includes engaging a second membrane layer of the reservoir bag with a pair of pinching grips, drawing the pinching grips toward one another to pinch the second membrane layer to form a tunnel in the membrane layer, and joining a first membrane layer to the second membrane layer to lock the tunnel in place.
• joining the first membrane layer to the second membrane layer includes engaging at least one of the first membrane layer and the second membrane layer with a heated sealing plate.
• FIG. 1 For storing a medicament.
• the reservoir bag includes a first membrane layer and a second membrane layer.
• the first membrane layer and the second membrane layer define a medicament chamber.
• At least one of the first membrane layer and the second membrane layer includes a tunnel extending at least partially into the medicament chamber.
• the first membrane layer is asymmetric relative to the second membrane layer.
• a surface area of the second membrane layer is greater than a surface area of the first membrane layer.
• a surface area of the second membrane layer is approximately the same as a surface area of the first membrane layer.
• the tunnel has a raised profile.
• the tunnel defines a flow channel in fluid communication with a port of the reservoir bag.
• the tunnel extends an entire length of the medicament chamber.
• the tunnel terminates at an intermediate location within the medicament chamber.
• the tunnel is sufficiently strong to maintain shape under vacuum produced by a pump of a drug delivery device to which the reservoir bag is connected. [0040] In some embodiments, the tunnel prevents the first and second membrane layers from laying entirely flat against one another.
• FIG. 1 Other embodiments of the present disclosure are directed to a filling station for filling a drug delivery device configured to deliver a medicament to a patient.
• the filling station includes an injector socket for receiving the drug delivery device, the drug delivery device including a reservoir bag receiving medicament, a cartridge socket for receiving a refill reservoir bag containing the medicament, and a pump configured to deliver the medicament from the refill reservoir bag to the reservoir bag of the drug delivery device.
• the refill reservoir bag includes a first membrane layer and a second membrane layer defining a medicament chamber. At least one of the first membrane layer and the second membrane layer includes a tunnel extending at least partially into the medicament chamber.
• the first membrane layer is asymmetric relative to the second membrane layer.
• the first membrane layer is symmetric relative to the second membrane layer.
• a surface area of the second membrane layer is greater than a surface area of the first membrane layer.
• a surface area of the second membrane layer is approximately the same as a surface area of the first membrane layer.
• the tunnel has a raised profile.
• the tunnel defines a flow channel in fluid communication with a port of the refill reservoir bag.
• the tunnel extends an entire length of the medicament chamber.
• the tunnel terminates at an intermediate location within the medicament chamber.
• the tunnel is sufficiently strong to maintain shape under vacuum produced by the pump.
• the tunnel prevents the first and second membrane layers from laying entirely flat against one another.
• FIG. 1 is a perspective view of a drug delivery device according to an embodiment of the present disclosure
• FIG. 2 is a cross-sectional view of the drug delivery device, taken along section line A-A of FIG. 1;
• FIG. 3 is a perspective view of the drug delivery device of FIG. 1, with the main cover and reservoir removed for clarity;
• FIG. 4 is a partial bottom view of the drug delivery device of FIG. 1;
• FIG. 5 is a partial cross-sectional view of the drug delivery device, taken along section line B-B of FIG. 4;
• FIG. 6 is a fluid path schematic diagram of the drug delivery device of FIG. 1;
• FIG. 7 is a schematic view of a reservoir bag of the drug delivery device of FIG. 1;
• FIG. 8 is a partial cross-sectional view of the reservoir bag of FIG. 7;
• FIG. 9 is cross-sectional view of a vacuum molding device for forming the reservoir bag of FIG. 7, according to an embodiment of the present disclosure
• FIG. 10 is cross-sectional view of a vacuum molding device for forming the reservoir bag of FIG. 7, according to an embodiment of the present disclosure
• FIG. 11 is cross-sectional view of a vacuum molding device for forming the reservoir bag of FIG. 7, according to an embodiment of the present disclosure
• FIG. 12 is cross-sectional view of a pinch-forming device for forming the reservoir bag of FIG. 7, in a first position, according to an embodiment of the present disclosure
• FIG. 13 is cross-sectional view of the pinch forming device of FIG. 12, in a second position
• FIG. 14 is a partial cross-sectional view of the reservoir bag of FIG. 7;
• FIG. 15 is a top view of the reservoir bag of FIG. 14;
• FIG. 16 is a perspective view of a filling station for a drug delivery, according to an embodiment of the present disclosure.
• FIG. 17 is a schematic diagram of a transfer tray of the filling station of FIG. 16, loaded with an on-body injector and a refill cartridge;
• FIG. 18 is a fluid path diagram of the transfer tray of FIG. 17; .
• first”, second, and the like are not intended to refer to any particular order or chronology, but instead refer to different conditions, properties, or elements.
• at least is meant “greater than or equal to”.
• not greater than is meant “less than or equal to”.
• the term “at least one of’ is synonymous with “one or more of’.
• the phrase “at least one of A, B, and C” means any one of A, B, and C, or any combination of any two or more of A, B, and C.
• “at least one of A, B, and C” includes one or more of A alone; or one or more of B alone; or one or more of C alone; or one or more of A and one or more of B; or one or more of A and one or more of C; or one or more of B and one or more of C; or one or more of all of A, B, and C.
• the term “at least two of’ is synonymous with “two or more of’.
• the phrase “at least two of D, E, and F” means any combination of any two or more of D, E, and F.
• “at least two of D, E, and F” includes one or more of D and one or more of E; or one or more of D and one or more of F; or one or more of E and one or more of F; or one or more of all of D, E, and F.
• fluidly connected in fluid communication
• derivatives thereof may be used interchangeably to mean a connection between a first component and a second component that allows fluids to flow from the first component to the second component and vice versa.
• the drug delivery device 1 generally includes components for piercing a patient’s skin and delivering medicament to the patient.
• the drug delivery device 1 includes a housing 10 having a main cover 2 liquid-sealed and/or hermetically sealed to a base 9.
• the base 9 houses and supports various components as described herein. The hermetic seal between the main cover 2 and the base 9 prevents fluids and particles from the outside environment from contaminating the internal components of the housing 10.
• the drug delivery device 1 may also include a vent or a vent membrane to provide pressure equalization within the housing 10.
• the base 9 may include an adhesive pad 70 for securing the drug delivery device 1 to the patient.
• FIG. 2 is a cross-sectional view of the drug delivery device 1 illustrating various internal components.
• the main cover 2 and the base 9 define an interior 12 which may be divided by a barrier 20 into a first internal region 14 and a second internal region 16.
• the drug delivery device 1 includes a reservoir bag 4 for storing a medicament (such as insulin), a pump 3 for pumping the medicament out of the internal reservoir bag 4, and a force sensing resistor 30 for detecting an amount of pressure in a medicament flow path.
• the drug delivery device 1 also includes electronics 8 for programming and operating the drug delivery device 1, and an insertion mechanism 7 for inserting a cannula 47 into a skin of the patient to deliver medicament.
• the reservoir bag 4 is an internal reservoir bag that is contained within the interior 12 of the housing 10.
• the reservoir bag 4 may be an external reservoir bag that is located outside the housing 10 and connected to the cannula 47 via tubing.
• the first internal region 14 of the interior 12 of the drug delivery device 1 includes components such as the pump 3, the force sensing resistor 30, and the electronics 8.
• the electronics 8 include semiconductor chips, controllers, diodes, antennas, coils, batteries, discrete components (resistors and capacitors, for example) and circuit boards used to operate and control the pump 3 and other electromechanical components of the drug delivery device 1. Due to the sensitive nature of the electronics 8, the first internal region 14 may be hermetically sealed and/or liquid-tight to prevent fluid ingress from the external environment.
• the second internal region 16 may include the insertion mechanism 7 and the cannula 47.
• the second internal region 16 is neither a hermetically sealed environment, nor a liquid-tight environment.
• a fill port 43 is provided in fluid communication with the reservoir bag 4 (not shown in FIG. 3) to facilitate filling of the reservoir bag 4 using a syringe or filling station 100 (shown in FIGS. 16-18).
• a receptacle 32 may be connected to the insertion mechanism 7 by tubing, for example, to transfer the medicament to the insertion mechanism 7 prior to injection into the skin of the patient.
• FIG. 4 illustrates a bottom surface 22 of the base 9 of the drug delivery device 1, prior to application of the adhesive pad 70 (shown in FIG. 1).
• the bottom surface 22 is oriented toward the skin of the patient, such that the bottom surface 22 is neither visible nor readily accessible without disconnecting the drug delivery device 1 from the patient.
• the bottom surface 22 of the base 9 may include first and second fluid channels 24, 26.
• the first and second fluid channels 24, 26 provide fluid pathways between various components such as the reservoir bag 4, the fill port 43, the force sensing resistor 30, the pump 3, and the insertion mechanism 7 (shown in, e.g., FIG. 2).
• the first and second fluid channels 24, 26 may be recessed from (or inscribed into) the bottom surface 22, and may be formed through a molding process, such as injection molding, or by a cutting process, such as milling. In other embodiments, the first and second fluid channels 24, 26 are disposed on the main cover
• the first and second fluid channels 24, 26 are sized such that flow rate of medicament is limited by the pump 3 and/or cannula 47 sizing, not by any flow restriction introduced by the first and second fluid channels 24, 26.
• the cross-sectional area of the first fluid channel 24 and the second fluid channel 26 may be greater than the gage of the cannula 47.
• the base 9 includes a fluid channel passageway 27 at each end of the first fluid channel 24 and the second fluid channel 26. As shown in FIG. 5, one of the fluid channel passageways 27 fluidly connects the receptacle 32 to a first end of the first fluid channel 24. Another of the fluid channel passageways 27 may fluidly connect the second end of the first fluid channel 27 to the pump
• one of the fluid channel passageways 27 may fluid connect a first end of the second fluid channel 26 to the fill port 43, and another of the fluid channel passageways 27 may fluidly connect a second end of the second fluid channel 26 to the pump 3.
• FIG. 6 is a schematic of an exemplary fluid path of the drug delivery device 1 in accordance with an embodiment of the present disclosure.
• the pump 3 draws medicament from the reservoir bag 4 via an inlet/outlet port 5 thereof, through a reservoir fluid channel 29 past the fill port 43, and into an inlet of the pump 3 via the second fluid channel 26.
• the pump 3 drives the medicament into the first fluid channel 24, and subsequently to the receptacle 32 of the insertion mechanism 7.
• the insertion mechanism 7 receives the medicament from the receptacle 32 via tubing, for example, and delivers the medicament through the cannula 47 to the skin of the patient.
• FIG. 7 shows the reservoir bag 4 separate from the drug delivery device 1 and in a substantially empty state.
• the reservoir bag 4 defines a medicament chamber 44 in fluid communication with an inlet/outlet port 5.
• the reservoir bag 4 may be constructed from compliant, flexible membranes joined along a border 50 to define the medicament chamber 44.
• the compliant, flexible membranes may include a first membrane layer 46 and a second membrane layer 48.
• the first and second membrane layers 46, 48 may be made of any suitable material, for example polyolefin/styrene block copolymer.
• the border 50 may be formed by heat sealing the first and second membrane layers 46, 48 to one another, for example in a press or mold.
• a tunnel 52 extends from the inlet/outlet port 5 at least partially into the medicament chamber 44.
• the tunnel 52 is defined in at least one of the first membrane layer 46 or the second membrane layer 48, and prevents the first and second membrane layers 46, 48 from laying entirely flat against one another.
• the tunnel 52 defines and maintains a flow channel 54 in fluid communication with the medicament chamber 44 and the inlet/outlet port 5.
• the tunnel 52 therefore prevents the medicament chamber 44 from self- sealing due to vacuum generated by the pump 3 pulling the first and second membrane layers 46, 48 against one another.
• the tunnel 52 is sufficiently strong to maintain shape under vacuum produced by the pump 3 during normal operation of the drug delivery device 1.
• the tunnel 52 extends an entire length of the medicament chamber 44, as shown in FIG. 7. In other embodiments, the tunnel 52 terminates at an intermediate location within the medicament chamber 44.
• FIG. 8 shows a sectional view of the tunnel 52 with the medicament chamber 44 substantially empty, illustrating how the tunnel 52 prevents the first and second membrane layers 46, 48 from lying flat against one another in a manner that could obstruct flow to the inlet/outlet port 5. This is particularly evident with the medicament chamber 44 nearly empty, when the first and second membrane layers 46, 48 are most susceptible to interfacing with one another in a manner that could obstruct flow.
• the tunnel 52 may have a raised profile, such as an arched profile, as shown in FIG. 8, though other curved and polygonal profiles are understood to be within the scope of the present disclosure.
• the tunnel 52 may be formed in the second membrane layer 48, so a surface area of the second membrane layer 48 is greater than a surface area of the first membrane layer 46.
• the first membrane layer 46 is asymmetric relative to the second membrane layer 48.
• the surface area of the second membrane layer 48 is approximately equal to the surface area of the first membrane layer 46.
• the first membrane layer 46 may be symmetric relative to the second membrane layer 48.
• the tunnel 52 is not actively formed in the reservoir bag 4 during manufacturing; but is rather a consequence of the difference in surface area and the asymmetry of the first and second membrane layers 46, 48. That is, as the medicament reservoir is emptied by the pump 3, the greater surface area of the second membrane layer 48 is forced to develop one or more folds to take up the extra surface area of the second membrane layer 48 relative to the first membrane layer 46. These one or more folds from the tunnel 52.
• FIGS. 9-13 illustrate various embodiments of tooling for forming the tunnel 52 in the reservoir bag 4. Referring first to FIGS. 9 and 10, a vacuum molding device 60 for forming the tunnel 52 is illustrated.
• the vacuum molding device 60 includes a die 62 defining a cavity 64 corresponding to the profile of the tunnel 52.
• a vacuum channel 66 extends from the cavity 64 to an external vacuum source 79.
• the first and second membrane layers 46, 48 are positioned on the die 62 overlaying the cavity 64.
• a vacuum applied to the vacuum channel 66 draws the second membrane layer 48 into the cavity 64 to form the tunnel 52 in the second membrane layer 48. While the second membrane layer 48 is drawn into the cavity 64, the first membrane layer 46 remains stationary, resulting in asymmetry of the first and second membrane layers 46, 48.
• the molding device 60 may include a sealing plate 68 to join the first membrane layer 46 to the second membrane layer 48 after the tunnel 52 has been formed. After being so joined, the first and second membrane layers 46, 48 cannot slide relative to one another, meaning the tunnel 52 is locked in place and cannot collapse.
• the sealing plate 68 includes one or more profiles 72, such as one or more prongs, which are heated by an external power source. The heated profiles 72 are brought into contact with the first and/or second membrane layers 46, 48 to create a spot weld 86 joining the first and second membrane layers 46, 48 to one another.
• FIG. 10 illustrates an embodiment of the molding device 60 in which the sealing plate 68 is positioned on the opposite side of the first and second membrane layers 46, 48 relative to the die 62.
• the sealing plate 68 is moved toward the die 62 in the direction of arrow D so that the one or more profiles 72 engage the first and/or second membrane layers 46, 48.
• FIG. 11 illustrates an alternate embodiment in which the sealing plate 68 is positioned below the die 62 (i.e. on the opposite side of the die 62 relative to the first and second membrane layers 46, 48).
• the one or more profiles 72 e.g. prongs
• the one or more profiles 72 extend through corresponding passageways 74 in the die 62, allowing the profiles 72 to engage the first and/or second membrane layers 46, 48 as the sealing plate 68 is advanced toward the die 62 in the direction of arrow E.
• a backing plate to retain the first and second membrane layers 46, 48 against the die 62 is not shown.
• FIGS. 12 and 13 illustrate an alternative embodiment of tooling for forming the tunnel 52.
• a pinch-forming device 80 for forming the tunnel 52 includes a pair of pinching grips 82 that engage the second membrane layer 48 on opposite sides of the tunnel to be formed.
• the pair of pinching grips 82 are connected to an actuator 84, such as a cylinder, that draws the pinching grips 82 toward one another.
• an actuator 84 such as a cylinder
• the tooling may further include a sealing plate 68 with one or more profiles 72 to join the first and second membrane layers 46, 48 to lock the tunnel 52 in place.
• FIG. 14 and 15 illustrate cross sections of the reservoir bag 4 with the tunnel 52 formed by the tooling of FIGS. 9-13.
• the reservoir bag 4 includes spot welds 86 where the one or more prongs 72 join the first membrane layer 46 to the second membrane layer 48.
• the reservoir bag 4 described in the present disclosure may be configured as a refill reservoir bag 300 for connection to an injector filling station 100 used to fill (and/or refill) one or more drug delivery devices 1.
• the refill reservoir bag 300 may include the same or similar features as the reservoir bag 4 described herein in connection with FIGS. 1-15.
• FIG. 16 an embodiment of an injector filling station 100 is illustrated in accordance with an embodiment of the present disclosure.
• the filling station 100 can include a base 110 and a lid 120.
• the lid 120 can be pivotally connected to the base 110, for example by a rotational hinge 130.
• the lid 120 includes a handle 122 to assist a user in manipulating the lid 120.
• the base 110 and/or the lid 120 can removably support a transfer tray 140.
• the tray 140 includes various features for supporting and removably retaining the drug delivery device 1 to filled, such as a snap-fit connector, bayonet connector, or the like.
• the tray 140 further includes various features for supporting and removably retaining the refill reservoir bag 300 containing medicament, such as a snap-fit connector, bayonet connector, or the like.
• the tray 140 includes various features for establishing fluid communication between the refill reservoir bag 300 and the reservoir bag 4 of the drug delivery device 1. In use, a user (typically a patient or the patient’s caregiver) loads an empty drug delivery device 1 and the refill reservoir bag 300 onto the tray 140.
• the tray 140, the base 110, and/or the lid 120 include various structures and components for transferring the medicament from the refill reservoir bag 300 into the reservoir of the drug delivery device 1, as will be described in connection with FIGS. 17 and 18.
• transfer of the medicament from the refill reservoir bag 300 into the reservoir bag 4 of the drug delivery device 1 may occur automatically upon closure of the lid 120.
• the drug delivery device 1 and the refill reservoir bag 300 can be removably connected to the tray 140 such that a fluid path is established between a medicament chamber 310 (corresponding to the medicament chamber 44 shown in FIG. 7) of the refill reservoir bag 300 and the medicament chamber 44 (as shown in FIG 7) of the reservoir bag 4 of the drug delivery device 1.
• the tray 140 includes a cartridge socket 142 for removably receiving the refill reservoir bag 300 and an injector socket 144 for removably receiving the drug delivery device 1.
• the tray 140 further includes a fluid path section 146 providing fluid communication between the cartridge socket 142 and the injector socket 144. As shown in FIG.
• the cartridge socket 142 can include a needle 143 for piercing a septum or stopper 320 of the refill reservoir bag 300 to provide fluid communication between the fluid path section 146 and the medicament chamber 310 of the refill reservoir bag 300.
• the injector socket 144 can include a needle 145 for piercing a septum or port 220 of the drug delivery device 1 to provide fluid communication between the fluid path section 146 and the medicament reservoir 210 of the drug delivery device 1.
• the fluid path section 146 can include one or more fluid channels 152 molded and/or formed into a base material 150 of the tray 140, and/or one or more tubing sections 148 connected to the base material 150.
• the tray 140 and/or other components of the filling station 100 include a pump 154 or other component for transferring medicament out of the refill reservoir bag 300 and into the reservoir bag 4 of the drug delivery device 1.
• the pump 154 can be disposed in the fluid path section 146.
• the pump 154 is controlled by an electronic controller 400 programmed or configured to actuate the pump 154 until a refill operation has been completed, and/or to abort the refill operation in the event of an error in loading or refilling the drug delivery device 1.
• an electronic controller 400 programmed or configured to actuate the pump 154 until a refill operation has been completed, and/or to abort the refill operation in the event of an error in loading or refilling the drug delivery device 1.
• the pump 154 is a peristaltic pump having one or more rollers 156 configured to engage a resilient tubing section 148 of the fluid path section 146 in order to draw medicament out of the refill reservoir bag 300 and inject the medicament into the reservoir bag 4 of the drug delivery device 1.
• the tray 140 may further include an inflation chamber 160 configured to inject a pre-inflation volume of air into the drug delivery device 1 prior to refilling the drug delivery device 1 with medicament.
• the inflation chamber 160 may be configured to inject a pre-fill inflation volume of approximately 100 microliters (pL) of air per injector refill operation.
• the inflation chamber 160 is disposed in fluid communication with the fluid path section 146 between the cartridge socket 142 and the injector socket 144 such that the inflation chamber 160 supplies air to the drug delivery device 1 via the fluid path section 146.
• the inflation chamber includes a piston 162 that moves axially to eject pressurized air from the inflation chamber 160.
• the tray 140 can further include a forward check valve 172 disposed in the fluid path section 146 between the drug delivery device 1 and the refill reservoir bag 300.
• the forward check valve 172 prevents flow of air and/or medicament back from the drug delivery device 1 into the refill reservoir bag 300.
• the tray 140 can further include a reverse check valve 174 disposed in the fluid path section 146 to allow air to escape from the fluid path section 146.
• the reverse check valve 174 can be disposed in a branch channel 153 of the fluid path section 146 arranged such that fluid can flow from the drug delivery device 1 to the reverse check valve 174 without flowing into the refill reservoir bag 300, and such that fluid can flow from the refill reservoir bag 300 to the reverse check valve 174 without flowing into the drug delivery device 1.
• the drug delivery device 1 and the refill reservoir bag 300 are in parallel fluid circuits relative to the reverse check valve 174.
• the cartridge socket 142 can include a port with which the refill reservoir bag 300 has a snap-fit connection.
• the cartridge socket 142 can include a bayonet connector, a threaded fitting, or other secure mechanical connection to engage and hold the refill reservoir bag 300.
• the cartridge socket 142 may exhibit tactile feedback, such as a snap fit, to confirm to the user that the refill reservoir bag 300 is properly inserted into the cartridge socket 142. Connection of the refill reservoir bag 300 to the cartridge socket 142 can automatically cause the needle 143 of the cartridge socket 142 to pierce the septum or stopper (which may, for example, be includes in the inlet/outlet port 5 as shown in FIG. 7) of the refill reservoir bag 300.
• the injector socket 144 can include a port with which the fill port 43 of the drug delivery device 1 has a snap-fit connection.
• the refill socket 142 may exhibit tactile feedback, such as a snap fit, to confirm to the user that the drug delivery device 1 is properly inserted into the injector socket 144. Connection of the drug delivery device 1 to the injector socket 144 can automatically cause the needle 145 of the injector socket 144 to pierce the septum of the drug delivery device 1.
• the pump 154 may be automatically actuated when the handle 122 of the filling station 100 is manipulated to close the lid 120. As explained above, the pump 154 then transfers medicament from the refill reservoir bag 300 to the reservoir bag 4 of the drug delivery device 1. The handle 122 may subsequently be raised to open the lid 120, and the refilled drug delivery device 1 can be removed and put into use.

Landscapes

• Health & Medical Sciences (AREA)
• Vascular Medicine (AREA)
• Engineering & Computer Science (AREA)
• Anesthesiology (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hematology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Dermatology (AREA)
• Infusion, Injection, And Reservoir Apparatuses (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=90455215

Family Applications (1)

Country Status (4)

Family Cites Families (4)

• 2023
  • 2023-09-22 WO PCT/US2023/033439 patent/WO2024064315A2/en not_active Ceased
  • 2023-09-22 JP JP2025517606A patent/JP2025532169A/ja active Pending
  • 2023-09-22 EP EP23868971.5A patent/EP4590364A2/de active Pending
  • 2023-09-22 CN CN202380067360.0A patent/CN119894552A/zh active Pending

Also Published As

Similar Documents

Legal Events